Emerging Science Webinar Series
At HPV Cancers Alliance, our vision is a world where no one faces an HPV cancer diagnosis and where compassionate, evidence-based care is the standard at every stage. The Emerging Sciences Webinar Series is one way we bring that vision to life.
These webinars foster collaboration between researchers, clinicians, and patient advocates, creating a dynamic space for innovative ideas and cutting-edge science. Each session features experts leading advancements in HPV-related healthcare, from novel treatments to comprehensive patient support.
Explore our growing library of webinars:
- Emerging Immunotherapies & Clinical Trials for HPV-Associated Cancers
- HPV Prevention, Access, & Outreach: Strategies to Improve Care
- Survivorship and Support: Intimacy, Healing, and Whole-Person Care
- Coming Soon: Infection & Early Detection
Emerging Science Webinar Resources:
Medical Societies / Non-Profit Organizations:
- American College of Obstetricians and Gynecologists
- American Sexual Health Association
- American Dental Association
- American Association of Cancer Research
- St. Jude Childrens Research Hospital HPV Cancer Prevention Program
- St. Jude – A Future Free of HPV Cancers
- Cancer Support Community – Education & Resrouces
News / Publications / Pharmaceutical Resources:
- (NEW) AACR – A Therapeutic HPV Vaccine Could Eliminate Precancerous Cervical Lesions
- Intimate Rose – Women’s Health
- JNCCN Strategies for Prevention and Control of HPV-Associated Cancers
- (NEW) St. Jude – Improving HPV Vaccination Coverage in The Last Frontier Takes a Community-Centered Approach
- Merck – HPV and related cancers: What you need to know
- Merck Vaccines – GARDASIL 9
- Merck – Clinical Trials
- Eisai – Community programs for oncology patients
- Eisai – Clinical Trials
- BioNTech – What are Clinical Trials
- BioNTech – Research & Innovation
- (NEW) BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
- Incyte – Patient Resources
- Incyte – HCP Resources
- (NEW) Incyte Announces FDA Approval Of Zynyz® (Retifanlimab-Dlwr) Making It The First And Only Approved First-Line Treatment For Advanced Anal Cancer Patients In The United States
Emerging Science Webinar Series Sponsors:
